Navigation Links
Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
Date:9/3/2007

opment, Cordis partners with interventional cardiologists worldwide to treat millions of patients who suffer from vascular disease. More information about Cordis Corporation can be found at http://www.cordis.com.

(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Cordis' expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 31, 2006. Copies of this Form 10-K, as well as subsequent filings, are available online at http://www.sec.gov, http://www.jnj.com or on request from Johnson & Johnson. Cordis does not undertake to update any forward-looking statements as a result of new information or future events or developments.)

*Cordis Corporation has entered into an exclusive worldwide license with Wyeth for the localized delivery of sirolimus in certain fields of use, including delivery via vascular stenting. Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceuticals, a division of Wyeth, under the name Rapamune(R). Rapamune i
'/>"/>

SOURCE Cordis Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. New Study Suggests Better Patient Outcomes with CYPHER Sirolimus-Eluting Coronary Stent than with Taxus Stent in Real-World Clinical Settings
2. Cypher Sirolimus-Eluting Coronary Stent Had Similar Results to Bypass Surgery and Better Outcomes Than Bare Metal Stents in Subgroup Analysis of Diabetic Patients With Multivessel Coronary Disease
3. Cypher Sirolimus-eluting Coronary Stent Had Similar Results to Bypass Surgery in Long-Term Study of Patients With Multi-Vessel Coronary Artery Disease
4. Two-Year Patient Registry Results Support Safety and Efficacy of Cypher Sirolimus-Eluting Coronary Stent in Real World Uses
5. New Point-of-Care Methods to Measure Coronary and Cerebrovascular Risk
6. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
7. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
8. Lipitor Reduced the Risk of Coronary Events by Half and Stroke by Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who Experienced a Recent Stroke
9. New Analysis of WHI Data Shows Reduced Levels of Coronary Artery Calcification, a Predictor of Cardiovascular Events, in Women aged 50-59 taking Estrogen Therapy
10. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
11. Abbott Announces Positive Nine-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... Md. , June 3, 2015  GenVec, Inc. ... with Dr. David T. Curiel and his ... at St. Louis (WUSTL).  Dr. ... and the Cancer Biology Division within the Department of ... and the WUSTL team will create modified versions of ...
(Date:6/3/2015)... MENLO PARK, Calif. , June 3, 2015 ... novel small molecule drugs for cardiovascular diseases, today ... MPH, has been appointed Chief Executive Officer, effective ... of experience in global, high-growth enterprises, with a ... the improvement of human health. With expertise that ...
(Date:6/3/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/6xfc66/europe_ct_market ) ... Market - Growth, Trends And Forecasts (2014 - 2019)" ... (CT) is an imaging process that customs special x-ray ... scans, of areas inside the body. It is also ... It is primarily used in the Cancer diagnosis process. ...
Breaking Medicine Technology:GenVec And Washington University at St. Louis Form Collaboration To Discover Targeted Adenovector-Based Therapeutics And Vaccines 2GenVec And Washington University at St. Louis Form Collaboration To Discover Targeted Adenovector-Based Therapeutics And Vaccines 3GenVec And Washington University at St. Louis Form Collaboration To Discover Targeted Adenovector-Based Therapeutics And Vaccines 4Armetheon Names Dr. Sanjay Kakkar as Chief Executive Officer 2Armetheon Names Dr. Sanjay Kakkar as Chief Executive Officer 3Armetheon Names Dr. Sanjay Kakkar as Chief Executive Officer 4Europe CT Market Report 2015-2019 - Growth, Trends And Forecasts 2
(Date:6/3/2015)... Justina Molzon, MS Pharm, JD will be honored ... Meeting. DIA’s Global Inspire Award program recognizes the organization’s ... commitment to service on a global scale. ... that recognizes the “Member of the Year” who consistently ... has contributed to the advancement of DIA’s mission. ...
(Date:6/3/2015)... 03, 2015 Researchers at the University ... mesothelioma and say the tried-and-true marker mesothelin is the ... article on the research. Click here to read ... Center for Asbestos Related Diseases say, even though a ... is still preferable to fibulin-3 for identifying mesothelioma. ...
(Date:6/3/2015)... June 03, 2015 Acne is the same ... be particularly stubborn to eliminate and hard to prevent. As ... in teens and young adults, in the years when the ... or oil,” says Jayme Bashian, director and lead medical aesthetician ... blackheads and cysts of acne are caused by oil and ...
(Date:6/3/2015)... First Choice Emergency Room , the ... United States, announced that it is opening its new ... , “I am pleased to announce that we are ... in the San Antonio area,” said Dr. James M. ... , First Choice Emergency Room is revolutionizing the ...
(Date:6/3/2015)... 03, 2015 Come on out in ... a 200-mile overnight relay beginning in Madison, Wisconsin on ... Saturday, June 13th. , For the 4th consecutive year, ... will run to raise money for the Brain Aneurysm ... members of the Neurosurgery staff from The University of ...
Breaking Medicine News(10 mins):Health News:Former FDA Official and U.S. Public Health Service Officer to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 2Health News:Former FDA Official and U.S. Public Health Service Officer to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 3Health News:Analysis Reveals Gold Standard Mesothelioma Biomarker Still the Best, According to Surviving Mesothelioma 2Health News:Back Acne: Tips for Clearer Summer Skin 2Health News:Back Acne: Tips for Clearer Summer Skin 3Health News:First Choice Emergency Room to Open New Facility in San Antonio, Texas 2Health News:4th Annual Ragnar Relay from Madison, WI to Chicago, IL Once Again Benefits Renowned Brain Aneurysm Foundation 2
... Protecting ... seeing up-close this summer simple and stylish , ... Miami, FL (PRWEB) June 2, 2010 -- VisAcuity.com today ... , , ,“We’ve invested nearly 12 months to gather this year’s exclusive collection of ...
... (May 29, 2010) -- Physician-scientists from NewYork-Presbyterian Hospital/Weill ... findings at the American Urological Association,s Annual Meeting ... Dr. Steven Kaplan, a urologist and ... Center, and Dr. Darracott Vaughan, senior author and ...
... A minimally invasive technique used to destroy kidney ... effectiveness as surgical removal of tumors in curbing cancer ... In an article available online in the journal ... and radiology at UT Southwestern Medical Center, reported the ...
... The National Institutes of Health (NIH) has awarded ... University a five-year, $3.9 million grant to study how ... Africa. The findings could alter public health approaches for ... "Most cases of XDR-TB are thought to arise when ...
... ... demanding enterprise customers with VMware and Microsoft Hyper-V environments. , ... (PRWEB) June 2, 2010 -- VKernel, the ... announced today the general availability of VKernel Optimization Pack 1.4. The latest version ...
... and perhaps more aggressive ones, found in heaviest men, study ... among prostate cancer patients appears to be linked to patient ... reveals. , The finding stems from work involving more ... 60 who underwent surgery between 2001 and 2007 to remove ...
Cached Medicine News:Health News:Sun Reading Glasses Collection Debuts 2Health News:NewYork-Presbyterian/Weill Cornell physician-scientists present at 2010 American Urological Meeting 2Health News:NewYork-Presbyterian/Weill Cornell physician-scientists present at 2010 American Urological Meeting 3Health News:Ablation proved as effective as traditional surgery in treating kidney cancer 2Health News:Einstein awarded NIH grant to study drug-resistant TB 2Health News:Einstein awarded NIH grant to study drug-resistant TB 3Health News:VKernel Raises Scalability and Reporting Bar with Optimization Pack 1.4 2Health News:Size of Prostate Tumor Linked to Patients' Weight 2
The Urine Legionella Antigen ELISA kit detects the presence of Legionella pneumophila serogroup1 antigen in urine....
Measles IgG ELISA....
Toxoplasma IgM II ELISA....
Herpes Simplex Virus 2 IgG ELISA....
Medicine Products: